Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.0015 | 0.1706 | 0.1706 |
Echinococcus granulosus | tyrosine protein kinase Fyn | 0.0043 | 1 | 1 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.003 | 0.6254 | 1 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.003 | 0.6254 | 0.6254 |
Brugia malayi | FAD binding domain containing protein | 0.0019 | 0.2748 | 0.2748 |
Giardia lamblia | Hypothetical protein | 0.0027 | 0.5212 | 0.5 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.003 | 0.6254 | 1 |
Schistosoma mansoni | tyrosine kinase | 0.0043 | 1 | 1 |
Echinococcus granulosus | tyrosine protein kinase Lyn | 0.0043 | 1 | 1 |
Loa Loa (eye worm) | TK protein kinase | 0.0038 | 0.8741 | 0.8662 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.003 | 0.6254 | 1 |
Trichomonas vaginalis | sulfite reductase, putative | 0.003 | 0.6254 | 1 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.003 | 0.6254 | 1 |
Chlamydia trachomatis | sulfite reductase | 0.0019 | 0.2748 | 0.5 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.003 | 0.6254 | 0.6017 |
Entamoeba histolytica | protein kinase, putative | 0.0034 | 0.745 | 1 |
Echinococcus granulosus | tyrosine protein kinase Src42A | 0.0037 | 0.8379 | 0.8379 |
Echinococcus multilocularis | tyrosine protein kinase Fgr | 0.0043 | 1 | 1 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.003 | 0.6254 | 0.6254 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0015 | 0.1636 | 0.5 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.003 | 0.6254 | 1 |
Echinococcus granulosus | tyrosine protein kinase Src42A | 0.0043 | 1 | 1 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.003 | 0.6254 | 0.6254 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.003 | 0.6254 | 1 |
Echinococcus multilocularis | tyrosine protein kinase Src64B | 0.0043 | 1 | 1 |
Brugia malayi | flavodoxin family protein | 0.003 | 0.6254 | 0.6254 |
Brugia malayi | flavodoxin family protein | 0.0012 | 0.0594 | 0.0594 |
Echinococcus multilocularis | tyrosine protein kinase Fyn | 0.0043 | 1 | 1 |
Echinococcus granulosus | tyrosine protein kinase Src64B | 0.0043 | 1 | 1 |
Echinococcus multilocularis | tyrosine protein kinase Src42A | 0.0043 | 1 | 1 |
Echinococcus multilocularis | tyrosine protein kinase Fyn | 0.0038 | 0.8741 | 0.8741 |
Echinococcus granulosus | tyrosine protein kinase Blk | 0.0038 | 0.8741 | 0.8741 |
Leishmania major | p450 reductase, putative | 0.003 | 0.6254 | 1 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0019 | 0.2748 | 0.229 |
Echinococcus multilocularis | methionine synthase reductase | 0.0019 | 0.2748 | 0.2748 |
Echinococcus granulosus | tyrosine protein kinase Fyn | 0.0043 | 1 | 1 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.003 | 0.6254 | 0.6254 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0015 | 0.1636 | 0.5 |
Plasmodium vivax | flavodoxin domain containing protein | 0.0027 | 0.5212 | 0.8159 |
Echinococcus multilocularis | tyrosine protein kinase lyn lyn a protein tyrosine kinase lymphocyte specific protein tyrosine kinase | 0.0043 | 1 | 1 |
Echinococcus multilocularis | tyrosine protein kinase lyn tyrosine protein kinase blk | 0.0043 | 1 | 1 |
Echinococcus granulosus | tyrosine kinase | 0.0038 | 0.8741 | 0.8741 |
Leishmania major | cytochrome P450 reductase, putative | 0.0027 | 0.5212 | 0.8159 |
Echinococcus granulosus | tyrosine protein kinase HCK | 0.0034 | 0.745 | 0.745 |
Echinococcus multilocularis | tyrosine protein kinase Blk | 0.0038 | 0.8741 | 0.8741 |
Treponema pallidum | flavodoxin | 0.0012 | 0.0594 | 0.5 |
Echinococcus multilocularis | tyrosine protein kinase Fyn | 0.0043 | 1 | 1 |
Echinococcus granulosus | 3'partial|tyrosine protein kinase Fgr | 0.0043 | 1 | 1 |
Echinococcus multilocularis | tyrosine protein kinase HCK | 0.0034 | 0.745 | 0.745 |
Schistosoma mansoni | cytochrome P450 reductase | 0.003 | 0.6254 | 0.6254 |
Echinococcus multilocularis | tyrosine protein kinase Src42A | 0.0037 | 0.8379 | 0.8379 |
Echinococcus granulosus | methionine synthase reductase | 0.0019 | 0.2748 | 0.2748 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0019 | 0.2748 | 0.2748 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.003 | 0.6254 | 1 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.0027 | 0.5212 | 0.5 |
Echinococcus granulosus | proto oncogene tyrosine protein kinase LCK | 0.0043 | 1 | 1 |
Echinococcus multilocularis | tyrosine protein kinase Srms | 0.0038 | 0.8741 | 0.8741 |
Trypanosoma cruzi | p450 reductase, putative | 0.003 | 0.6254 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.003 | 0.6254 | 0.6017 |
Echinococcus multilocularis | tyrosine protein kinase Fyn | 0.0043 | 1 | 1 |
Echinococcus granulosus | tyrosine protein kinase Fyn | 0.0043 | 1 | 1 |
Echinococcus granulosus | tyrosine kinase|tyrosine protein kinase Fyn | 0.0038 | 0.8741 | 0.8741 |
Loa Loa (eye worm) | TK protein kinase | 0.0034 | 0.745 | 0.7289 |
Schistosoma mansoni | tyrosine kinase | 0.0043 | 1 | 1 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.003 | 0.6254 | 0.5 |
Trichomonas vaginalis | NADPH fad oxidoreductase, putative | 0.0027 | 0.5212 | 0.8159 |
Schistosoma mansoni | diflavin oxidoreductase | 0.0015 | 0.1636 | 0.1636 |
Brugia malayi | protein-tyrosine kinase | 0.0038 | 0.8741 | 0.8741 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.003 | 0.6254 | 1 |
Loa Loa (eye worm) | SRC-1 | 0.0043 | 1 | 1 |
Brugia malayi | FAD binding domain containing protein | 0.003 | 0.6254 | 0.6254 |
Echinococcus multilocularis | proto oncogene tyrosine protein kinase LCK | 0.0043 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.003 | 0.6254 | 1 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.003 | 0.6254 | 1 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.